The pharmacological management of osteoporosis.

Abstract

Pharmacotherapy is effective in decreasing the incidence of osteoporotic fracture, morbidity, and mortality. This benefit is pronounced in patients at highest risk for fracture: those with prior osteoporotic fracture, very low bone mineral density, or receiving chronic corticosteroid treatment. We review the best pharmacotherapeutic options currently available for treating osteoporosis.

• Authors: Amy E Riek, Dwight A Towler
• Journal: Missouri medicine (Mo Med) 2011 Mar-Apr Vol. 108 Issue 2 Pg. 118-23 ISSN: 0026-6620 [Print] United States
• PMID: 21568234 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bone Density Conservation Agents
• RANK Ligand
• Selective Estrogen Receptor Modulators
• Teriparatide
• Denosumab

Topics

• Absorptiometry, Photon
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bone Density Conservation Agents (therapeutic use)
• Denosumab
• Humans
• Osteoporosis (drug therapy)
• Osteoporotic Fractures (epidemiology)
• RANK Ligand (therapeutic use)
• Risk Factors
• Selective Estrogen Receptor Modulators (therapeutic use)
• Teriparatide (therapeutic use)